WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsNexgel Inc (NXGL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 243596% more annual revenue ($28.43B vs $11.67M). MDLN leads profitability with a 4.1% profit margin vs -24.7%. MDLN earns a higher WallStSmart Score of 52/100 (C-).

MDLN

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 8.3Quality: 7.8
Piotroski: 4/9

NXGL

Avoid

28

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDLNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$66.92

Current Price

$42.03

$24.89 discount

UndervaluedFair: $66.92Overvalued

Intrinsic value data unavailable for NXGL.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN0 strengths · Avg: 0/10

No standout strengths identified

NXGL1 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
29.9x4/10

Moderate valuation

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

NXGL4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$15.55M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-52.8%2/10

ROE of -52.8% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

Revenue growth of 14.8% demonstrates continued momentum.

Bull Case : NXGL

The strongest argument for NXGL centers on Price/Book.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Bear Case : NXGL

The primary concerns for NXGL are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MDLN profiles as a value stock while NXGL is a turnaround play — different risk/reward profiles.

MDLN is growing revenue faster at 14.8% — sustainability is the question.

NXGL generates stronger free cash flow (-793,000), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 28/100) and 14.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Nexgel Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

NEXGEL, Inc. manufactures aqueous, electron beam crosslinked, high water content hydrogels and polymeric gels. The company is headquartered in Langhorne, Pennsylvania.

Want to dig deeper into these stocks?